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ABSTRACT
Lymphangiomatosis, a rare disorder of the
lymphatic system characterized by the
abnormal proliferation of lymphatic vessels, is
a typically benign disorder that at times can
exhibit invasive or malignant behavior. While
generally considered a diagnosis of childhood,
in adults the majority of cases are asymptomatic
and found incidentally. Rarely, lymphatic
overgrowth can occur, causing growth of
lesions on imaging mimicking a metastatic
process and occasionally, resulting in
substantial morbidity and mortality. Here, we
present such a case of lymphangiomatosis with
multi-organ system involvement in liver, bone,
and spleen. In addition to details of the clinical
presentation and the pathologic review which
led to the diagnosis, we describe our use of the
tyrosine kinase inhibitor pazopanib, which may
cause stabilization of lymphangiomatosis
through blockade of vascular endothelial
growth factor (VEGF) signaling, for systemic
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INTRODUCTION
Many oncologists will encounter patients
whose tumors display benign histology and
invasive or malignant behavior. This is
particularly relevant as new pathologic entities
emerge due to novel discoveries in the field,
advances in molecular diagnostics, and tumor
reclassifications. One example of a benign
entity that can occasionally exhibit aggressive
behavior is lymphangiomatosis, a rare disorder
of the lymphatic system characterized by the
abnormal proliferation of lymphatic vessels,
sometimes referred to as generalized lymphatic
anomaly. When focal these malformations are
termed lymphangiomas, but when widespread
the process is referred to as lymphangiomatosis
[1–5]. This disorder is histologically benign, as
organs are replaced by structurally normal
lymphatic channels and cellular components
are mature and well differentiated [3].
Lymphangiomatosis is generally a disease of
childhood, with most cases being diagnosed by
the second decade of life [2–5].
In adults, the majority of cases of
lymphangiomatosis are asymptomatic and
often found incidentally on imaging ordered
for unrelated conditions. Symptomatic disease,
while rare, does occur and tends to be caused by
compressive effects or organomegaly and the
resulting sequelae [4, 5]. However, lymphatic
overgrowth can cause substantial morbidity, and
occasionally mortality, through local tissue
destruction. Historically lymphangiomatosis
has been shown to cause pulmonary, splenic or
skeletal disease, though it has also been found in
locations such as the intestine, extremities, head
and neck, and heart [2–5]. The variable
presentation of lymphangiomatosis and the
rare incidence of symptomatic cases requiring
treatment have made establishing treatment
guidelines difficult. The mainstay of treatment
continues to be resection when possible for
localized disease, with palliation being the goal
in cases of diffuse spread [1, 3, 4]. Sclerotherapy
and radiotherapy have been tried to no avail, and
systemic corticosteroids and chemotherapeutic
agents such as cyclophosphamide and cytokine
interferon (IFN) have shown either mixed results
or had significant side effects [5–15]. There has
been some promising anecdotal evidence for the
use of angiogenesis and lymphangiogenesis
inhibitors such as vascular endothelial growth
factor (VEGF) and mammalian target of
rapamycin (mTOR) inhibitors. Indeed, clinical
benefit was reported in one case of diffuse
pulmonary lymphangiomatosis treated with
the VEGF inhibitor bevacizumab [1], as well as
in an infant treated with the mTOR inhibitor
sirolimus [5]. These approaches make scientific
sense given the off-target antiangiogenic effects
of mTOR inhibitors by way of inhibition of
kinase activity resulting in cell death, and the
role of VEGF in lymphangiogenesis, which is
primarily driven by the interaction of VEGF-C
and D isoform signaling through VEGF-receptors
2 and 3, and also by the VEGF-A isoform through
VEGF receptor 2 [1]. Here, we present a case of
lymphangiomatosis with multi-organ system
involvement in an adult with growing lesions
that was treated with pazopanib, an orally
available potent and selective small molecule
tyrosine kinase inhibitor targeting VEGFR 1-3,
platelet-derived growth factor receptors (PDGFR)
a/b, and c-kit [16].
CASE REPORT
The patient was agreeable to having her images
and clinical history published in this report.
The patient is a 33-year-old female with a past
medical history significant only for a
complicated twin pregnancy following in vitro
fertilization four years prior, who presented to
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the emergency department complaining of
chest pain and dyspnea. A computed
tomography angiogram (CTA) performed at
that time was negative for pulmonary
embolism, but found incidental pulmonary
nodules without further parenchymal or
vascular lung abnormalities, as well as sclerosis
of the T7 vertebral body and multiple
enhancing lesions in the liver and spleen
peripherally. Her dyspnea improved and she
followed up with her primary physician as an
outpatient. Although her symptoms were likely
unrelated to the CTA findings, a triphasic CT of
the abdomen and pelvis was repeated and
confirmed a sclerotic T7 vertebral body,
scattered sclerotic foci throughout the spine, a
9 mm nodule in the left lower lobe of the lung,
multiple hypodense lesions in the liver with the
largest 5.5 9 3.3 cm in the left lobe, and an
enlarged spleen with hypodense lesions
measuring 11.4 9 6.4 cm in size (see Figs. 1, 2).
There was no identifiable adenopathy. A
magnetic resonance imaging (MRI) of the
abdomen was performed and again showed
multiple large hepatic lesions, the largest in
the left lobe now 9 cm, and multiple splenic
lesions, the largest now 13 cm, that did not
demonstrate typical MR characteristics of
hemangiomas. Hemogram and chemistry
profile were normal. CEA, CA 125, CA 19-9
and alpha fetoprotein levels were all within
normal limits.
Upon presentation to us the patient denied
any constitutional complaints and her dyspnea
had completely resolved. A comprehensive
physical exam was pertinent for a palpable
spleen but no appreciable hepatomegaly or
lymphadenopathy, no tenderness to palpation
over her vertebral spine and no other abnormal
signs. Because of the uncharacteristic
radiographic findings, the sclerotic bony
disease and the marked progression in size of
the lesions in the short time between scans, the
appearance was felt to be overall indicative of a
metastatic process and an ultrasound guided
liver biopsy was performed. The biopsy showed
well-formed vessels embedded in fibrous stroma
infiltrating into the hepatic parenchyma. The
vessels were lined with flattened, focally
enlarged and mildly atypical endothelial cells
with focal cytoplasmic vacuolization. They
showed immunoreactivity for VIII-related
Fig. 1 Initial computed tomography demonstrating the
presence of hepatic (arrows) and splenic (arrowhead)
lesions consistent with a multifocal or metastatic process
Fig. 2 Initial computed tomography demonstrating the
presence of a pulmonary nodule (arrowhead) consistent
with a multifocal or metastatic process
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antigen, CD31, CD34, and podoplanin (D240),
consistent with lymphatic endothelial
phenotype. The tumor cells were negative for
keratins CK7 and CK8 (CAM5.2), typically
positive in epithelial cells. These results
supported a diagnosis of a vascular neoplasm
with clear cell features and a littoral cell
phenotype. The original differential diagnosis
included bacillary angiomatosis, though there
was no evidence of immunocompromise, and
littoral cell angioma because of the histologic
phenotype and known case reports of this
process to involve both the liver and spleen
[17]. Given the clinical features of additional
metastatic appearing lesions, however, the
diagnosis of a hemangioendothelioma or a
low-grade, unusual clear cell angiosarcoma
could not be excluded [17, 18]. At that time, it
was felt a second biopsy should be obtained to
further characterize the lesions outside the liver,
and since several weeks had passed, repeat
imaging was ordered to re-assess their behavior.
The patient was again seen in follow-up and
the repeat CT of the chest, abdomen and pelvis
was obtained which showed further increase in
the size of the hepatic lesions, growth of the
spleen from 11.5 to 13.6 cm in greatest
dimension and increased central hypodensity
in the spleen compatible with necrosis. Both
bone and lung lesions were stable. Interim
repeat hemogram also showed new
thrombocytopenia of 133,000. CT-guided core
needle biopsy of the spleen was chosen based
on imaging and showed a tumor
morphologically similar to the hepatic lesion,
with a benign process with clear cell changes
involving both specimens. Both hepatic and
splenic specimens were sent for additional peer
review at that time. It was noted there that the
vascular profiles often contained proteinaceous
fluid and lymphocytes supporting lymphatic
vascular-type proliferation, with focal
endothelial hobnailing. The lymphatic
endothelial cells were again positive for CD31,
CD34, and podoplanin but negative for keratin
8 (CAM 5.2), keratin 7, and CD45 (Fig. 3). Given
that the morphology and immunophenotype
supported the diagnosis of lymphangiomatosis,
and that this process may involve liver, spleen
and bone as well as exhibit growth in rare cases,
it was agreed that this diagnosis was most
accurate.
With the observed short-term growth and
necrosis particularly in the spleen, as well as
developing thrombocytopenia, systemic
therapy was recommended for this patient.
Pazopanib, a potent and selective tyrosine
kinase inhibitor of VEGF-receptors 1, 2, and 3
as well as KIT and PDGF receptors, was chosen
based on the initial possible working diagnoses
of low-grade angiosarcoma versus a metastatic
littoral cell tumor of the spleen, its kinase
profile (active against VEGF signaling) and
regulatory approval in advanced sarcomas. The
patient was started on 800 mg of pazopanib by
mouth daily. Although no reduction in the size
of the lesions was noted, growth of the splenic
and liver lesions stabilized on follow-up
imaging and the patient’s hemogram
normalized. The disease remains stable after
one year of therapy. The patient has
experienced minimal treatment related side
effects consisting of minimal nausea, and is
clinically well at this time.
DISCUSSION
As clinicians, questions of monitoring and
treatment are raised by cases of ‘‘malignant
masqueraders’’ such as the one above. Indeed,
the presentation of lymphangiomatosis with
multi-organ involvement has been mistaken for
advanced, metastatic cancers such as melanoma
[4]. The lesions observed in this patient
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demonstrated stabilization after administration
of pazopanib, known to have antiangiogenic
effects, in keeping with the above-mentioned
case reports showing indications of clinical
benefit with VEGF inhibitors in patients with
symptomatic lymphangiomatosis.
Certainly, no general conclusions regarding
treatment can be made from this case
presentation, especially given that
lymphangiomatosis is a usually benign entity
that does not cause systemic issues. It is likely
that this entity, like many tumors,
demonstrates a spectrum of aggression, with
some tumors progressing more rapidly than
others and rarely transforming into a life
threatening condition. In patients with
lymphangiomatosis that is symptomatic or
spreading, careful attention to disease
‘‘tempo’’, or the rate of spread based on
imaging and/or clinical decline would play an
important role in any decisions to institute
systemic treatment. Without additional data,
treatment and monitoring decisions for these
patients must currently be made on a case by
case basis with prudent scientific and clinical
consideration. Judicious use of antiangiogenic
agents is particularly important since
antiangiogenic agents as a class may produce
Fig. 3 Lymphangiomatosis involving spleen and liver. a,
b Lymphangiomatosis involving the spleen shows
parenchymal replacement by vascular proliferation.
The lumina are lined by attenuated endothelial cells
and contain variably proteinaceous material.
c Lymphangiomatosis involving the liver contains
vascular proﬁles in ﬁbrous stroma. Some proﬁles have
vacuolated inward protuberant (‘‘hobnail’’) endothelia.
d The endothelial cells are immunohistochemically
positive for podoplanin (red chromogen)
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side effects such as hypertension, proteinuria,
impaired wound healing, and events of life
threatening vascular compromise [19]. One
possible solution is the modification of
existing or future phase I clinical trials of
antiangiogenic agents to allow the inclusion of
patients afflicted by lymphangiomatosis or
giant hemangiomas who are symptomatic and
afflicted by progressive disease or disease
causing deterioration in the patient’s quality
of life.
CONCLUSION
The authors report above a case of an adult with
lymphangiomatosis involving multiple organs
treated with pazopanib with suggestion of
clinical benefit. In the face of this mysterious,
usually benign disease process which may rarely
exhibit aggressive behavior, the authors
encourage reports of additional cases to add to
the scant literature on this subject and assist in
future diagnostic and therapeutic dilemmas.
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